96 - Solar Urticaria Flashcards
Subforms of chronic inducible urticaria
Physical urticaria
Cholinergic urticaria
Contact urticaria
Aquagenic urticaria
Solar urticaria usually is primary, where the cause is unknown. Very rarely, solar urticaria is linked to _____ and is then termed secondary solar urticaria
Cutaneous porphyria
Systemic lupus erythematosus
Solar urticaria predominantly affects
Women in the third decade of life
Wheals in solar urticaria generally develop within _____ of exposure and disappear usually within _____ of cessation of exposure
A few minutes up to 1 hour
1 hour and after a maximum of 24 hours
Solar urticaria typically affects skin areas that are _____ and spares the skin sites that are _____
Normally shielded by clothing
Frequently exposed to light such as the hands and face
Characterized by the reoccurrence of light-induced whealing in the same location
Fixed SolU
Onset of signs and symptoms after UV exposure is delayed by up to several hours
Delayed SolU
Skin mast cell degranulation in SolU is due to exposure of the skin to _____, less commonly _____, and, rarely, _____ radiation
UVA (320 to 400 nm), visible (400 to 600 nm)
UVB (280 to 320 nm)
Infrared (>600 nm)
Y/N: The histopathologic features of SolU allow for its distinction from other forms of urticaria
No - do not allow
Phototesting is performed by exposing patients to ultraviolet radiation and visible light at skin sites that have been protected from light for several days, most commonly the
Buttocks
Threshold testing determines the _____, a marker of disease activity and response to therapy
Minimal urticarial dose
Reasons for a negative phototest in patients with SolU
Signs and symptoms limited to erythema in some patients
Prior intake of antihistamines or other medications that inhibit the development of wheals
Refractoriness of the skin due to previous light exposure of the test site
Recommended first-line treatment for solar urticaria
Nonsedating H1 antihistamines at standard dose
Alpha-MSH analog and melanocortin receptor agonist recently licensed for the treatment of erythropoietic protopophyria
Shown to protect SolU patients from the development of signs and symptoms
Afamelanotide
Alpha-MSH analog and melanocortin receptor agonist recently licensed for the treatment of erythropoietic protopophyria
Shown to protect SolU patients from the development of signs and symptoms
Afamelanotide